跳至主要内容
临床试验/CTRI/2021/05/033754
CTRI/2021/05/033754尚未招募未知

Efficacy and Safety of Ripasudil in the Treatment of Primary open angle glaucoma and Ocular Hypertension

Dr Sowparnika A B0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Newly detected POAG / OHT.
  • 2. POAG will be defined as:
  • a. IOP > 21 mmHg on atleast 2 occasions, atleast 24 has apart.
  • b. Optic nerve head showing CDR > 0.61 with significant thinning of the neuroretinal rim: or a CDR asymmetry of 0.2 > between 2 eyes.
  • c. Open angles on gonioscopy.
  • d. Automated visual field testing showing changes corresponding with the optic disc changes.
  • 3. OHT will be defined as:
  • IOP > 21 mmHg on atleast 2 occasions, 24 hrs apart.
  • Open angles on gonioscopy
  • Normal optic disc and visual field tests
  • 4. Patients willing to participate in the study given a written informed consent and comply with the followup schedule.

排除标准

  • 1. Patients with POAG / OHT having IOP > 30 mmHg.
  • 2. Patient with PACG and others secondary glaucoma.
  • 3. Patient underwent surgery on the inner eye
  • 4. Patient who changed glaucoma treatment after ripasudil administration

研究者

发起方
Dr Sowparnika A B

相似试验